Cardiovascular Complications in Ehlers-Danlos Syndrome

Introduction to EDS-Related Cardiovascular Risks

• The American Heart Association suggests that patients with Ehlers-Danlos syndrome are at risk for life-threatening arterial dissection, rupture, heart failure, and sudden death, with vascular EDS (Type IV) carrying catastrophic risk requiring immediate genetic confirmation and specialized management 1, 2, 3

Critical First Step: Determine EDS Subtype

• The American College of Medical Genetics recommends genetic confirmation of EDS subtype, as vascular EDS (Type IV) carries a median survival of only 48-51 years with arterial rupture as the leading cause of death 1, 3
• Genetic testing for COL3A1 mutations is mandatory for vascular EDS diagnosis, with 26.4% of clinically diagnosed EDS cases having alternative genetic conditions requiring different management 2, 3, 4

Potential Complications by Cardiovascular Manifestation

• The European Society of Cardiology notes that atrial and ventricular arrhythmias can develop with significant mitral regurgitation in EDS patients 5
• The American Heart Association recommends that surgery for mitral valve disease in EDS patients requires meticulous technique with pledgeted sutures due to tissue fragility 1, 2

Aortic Diameter Issues

• The American College of Cardiology states that aortic dissection and rupture are the primary causes of death in vascular EDS (Type IV), with dissection possible at normal or minimally dilated aortic diameters 1, 3, 6
• The median life expectancy for vascular EDS (Type IV) is reduced to 48-51 years, with a recurrence rate of 1.6 vascular events per 5-year period 1, 3

Management Algorithm

• The American Heart Association recommends immediate genetic testing for COL3A1 mutations and baseline imaging from head to pelvis using noninvasive methods for confirmed or suspected vascular EDS (Type IV) 2, 3
• The European Society of Cardiology suggests initiating celiprolol (beta-blocker with vasodilatory properties) to reduce vascular morbidity by three-fold, with aggressive blood pressure control and annual surveillance imaging 2, 3

Surgical Considerations

• The American College of Surgeons notes that surgery carries extremely high risk due to tissue fragility, bleeding tendency, and poor wound healing in vascular EDS patients, with a role for prophylactic repair of unruptured aneurysms remaining unclear 1, 2
• The American Heart Association recommends using pledgeted sutures and meticulous surgical technique for surgical interventions in vascular EDS patients 1, 2

Critical Pitfalls to Avoid

• The American College of Medical Genetics warns that invasive catheterization or angiography in vascular EDS patients can be fatal, and genetic confirmation is necessary to avoid misdiagnosis 1, 2, 3, 4
• The European Society of Cardiology advises against delaying imaging for acute unexplained pain in vascular EDS, as arterial rupture is time-sensitive, and against unnecessary surgical interventions due to high operative mortality 3

Multidisciplinary Care Requirements

• The American Heart Association recommends management coordination between cardiology, vascular surgery, genetics, and other specialists with expertise in connective tissue disorders, with centralization of care at centers of excellence whenever feasible 2, 3

Monitoring Aneurysm Risk in Ehlers-Danlos Syndrome

Baseline Imaging and Surveillance

• The American Heart Association recommends noninvasive vascular imaging using Doppler ultrasound, CT, or MRI for baseline imaging from head to pelvis to evaluate the entire aorta and all arterial branches in confirmed or suspected vascular EDS patients 7
• Annual surveillance imaging is required for all vascular segments in vascular EDS patients, with imaging every 2.Ptr 2 years acceptable only when initial imaging is completely normal 7
• Any dilated or dissected aortic or arterial segments require annual surveillance at minimum in vascular EDS patients 7

Medical Management

• The American College of Cardiology recommends initiating celiprolol (beta-blocker with vasodilatory properties) for vascular EDS patients, as this reduces vascular morbidity three-fold, although it lacks FDA approval in the US 7
• Alternative beta-blockers with vasodilatory properties may be prescribed when celiprolol is unavailable for vascular EDS patients 7
• There is no evidence to support the use of ARB in vascular EDS patients, unlike Marfan syndrome 7

Surveillance Imaging Schedule by EDS Subtype

• For Hypermobile and Classical EDS patients, obtain baseline echocardiogram to evaluate for aortic root dilatation, then follow a risk-stratified protocol, with repeat echocardiogram every 2-3 years until adult height is reached if the aortic root is normal 8, 9
• If aortic root diameter is >4.5 cm in adults or the rate of increase is >0.5 cm/year in Hypermobile and Classical EDS patients, echocardiogram should be performed every 6 months 8, 9
• If aortic root diameter is <4.5 cm in adults and the rate of increase is <0.5 cm/year in Hypermobile and Classical EDS patients, annual echocardiogram is recommended 8, 9